Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
MiNK Therapeutics Inc (INKT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$10.05-5.19%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for INKT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advance ARDS Phase 2 and GVHD clinical data in 2026 | MiNK is advancing key clinical trials like ARDS Phase 2 in 2026. | Improving | Failure to initiate ARDS Phase 2 or release GVHD data in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “The initial agenT-797–treated patients were alive and afebrile at Day 28, with improved oxygenation and liberation from ventilator and vasopressor support.” “Enrollment continues in Lviv, and activation of U.S. clinical centers is underway.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
INKT is a high-risk clinical-stage healthcare company, with its long-term case tied to progress in its programs rather than established earnings. Management has advanced clinical work and shown expense discipline, but the thesis remains in a watch state after a recent earnings miss.
The evidence snapshot provides no valuation measure or specific account of market expectations, so it is not possible to judge whether the shares look cheap, fair, or expensive versus peers. Losses and high risk are clear, while the recent earnings miss has weighed on the thesis; confidence in this assessment is low.
Near term, INKT is likely to keep reporting losses as it advances clinical programs, with recent net losses and declining cash showing the cost of that work. Management has reported positive initial Day 28 observations in its Phase 2 acute lung injury and ARDS trial and has improved losses over time, but cash use and a recent earnings miss remain risks.
The multi-year thesis depends on clinical data, including ARDS and GVHD updates, and on management’s ability to fund that work while controlling expenses. Near term, a guidance cut or further weakening in jobs data could add pressure, while continued strength among healthcare sector bellwethers could support sector momentum.
Over the next 1 to 3 years, INKT remains a low-confidence, high-risk clinical development story with signs of execution progress but limited financial cushion and uneven recent performance. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reduce net losses toward -$2.74M by 2026-Q1 | Net losses improved from -$4.24M to -$2.74M recently. | Under Pressure | Net losses worsen beyond -$2.74M in 2026-Q1 | Net income: $-3.128M FY2026-Q2; GAAP. Published target: Net income >= -$2.74M in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 2026-3,128,201 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Financial Results Cash and cash equivalents were $8.8 million as of June 30, 2026, compared with $9.5 million as of March 31, 2026, and $13.4 million as of December 31, 2025.” “The year-over-year improvement reflects continued expense discipline.” Net income was $-3.128 million in 2026-Q2. Delivery assessment Nov 5, 2026 |
Improve operating income toward -$2.88M by 2026-Q1 | A supporting condition in MiNK Therapeutics Inc's published investment case. The stated target is Operating income >= -$2.88M in 2026-Q1. | Intact | Operating income worsens beyond -$2.88M in 2026-Q1 | Operating income: $-3.217M FY2026-Q2; GAAP. Published target: Operating income >= -$2.88M in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 2026-3,216,894 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Financial Results Cash and cash equivalents were $8.8 million as of June 30, 2026, compared with $9.5 million as of March 31, 2026, and $13.4 million as of December 31, 2025.” “The year-over-year improvement reflects continued expense discipline.” Net income was $-3.128 million in 2026-Q2. Delivery assessment Nov 5, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.85 → $-2.19 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-07-25 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-07-26 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-07-27 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-07-28 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-07-29 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-07-30 | $-2.85 | $0 | 2 / 2 |
| 2026-07-31 | $-2.85 | $0 | 2 / 2 |
| 2026-08-01 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-08-02 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-08-03 | $-2.85 | $0 | 2 / 2 |
| 2026-08-04 | $-2.85 | $0 | 2 / 2 |
| 2026-08-05 | $-2.85 | $0 | 2 / 2 |
| 2026-08-06 | $-2.85 | $0 | 2 / 2 |
| 2026-08-07 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-08-08 | $-2.85 | $0 | 2 / 2 |
| 2026-08-09 | $-2.85 | $0 | 2 / 2 |
| 2026-08-10 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-08-12 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-08-13 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-08-14 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-08-15 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-08-16 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-08-17 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-08-18 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-08-19 | $-2.85 | $4,400,000 | 2 / 2 |
| 2026-08-20 | $-2.85 | $4,400,000 | 2 / 1 |
| 2026-08-21 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-08-22 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-08-23 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-08-24 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-08-25 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-08-26 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-08-27 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-08-28 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-08-29 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-08-30 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-08-31 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-01 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-02 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-03 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-04 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-05 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-06 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-07 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-08 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-09 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-10 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-11 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-12 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-13 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-14 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-15 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-16 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-17 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-18 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-19 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-20 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-21 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-22 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-23 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-24 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-25 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-26 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-27 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-28 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-29 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-09-30 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-10-01 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-10-02 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-10-03 | $-2.65 | $4,000,000 | 2 / 1 |
| 2026-10-04 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-05 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-06 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-07 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-08 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-09 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-10 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-11 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-12 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-13 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-14 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-15 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-16 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-17 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-18 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-19 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-20 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-21 | $-2.65 | $4,000,000 | 1 / 1 |
| 2026-10-22 | $-1.97 | $4,000,000 | 1 / 1 |
| 2026-10-23 | $-2.19 | $2,750,000 | 1 / 1 |
| 2026-10-24 | $-2.19 | $2,750,000 | 2 / 1 |
| 2026-10-25 | $-2.19 | $2,750,000 | 2 / 2 |
| 2026-10-26 | $-2.19 | $2,750,000 | 2 / 2 |
| 2026-10-27 | $-2.19 | $2,750,000 | 2 / 2 |
| 2026-10-28 | $-2.19 | $2,750,000 | 2 / 2 |
| 2026-10-29 | $-2.19 | $2,750,000 | 2 / 2 |
| 2026-10-30 | $-2.19 | $2,750,000 | 2 / 2 |
| 2026-10-31 | $-2.19 | $2,750,000 | 2 / 2 |
| 2026-11-01 | $-2.19 | $2,750,000 | 2 / 2 |
| 2026-11-02 | $-2.19 | $2,750,000 | 2 / 2 |
| 2026-11-03 | $-2.19 | $2,750,000 | 2 / 2 |
| 2026-11-04 | $-2.19 | $2,750,000 | 2 / 2 |
| 2026-11-05 | $-2.19 | $2,750,000 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.